Shield Therapeutics (LSE:STX) Additional Paid-In Capital : £173.09 Mil(As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Additional Paid-In Capital?

Shield Therapeutics's quarterly additional paid-in capital increased from Jun. 2022 (£114.64 Mil) to Dec. 2022 (£116.26 Mil) and increased from Dec. 2022 (£116.26 Mil) to Jun. 2023 (£173.09 Mil).

Shield Therapeutics's annual additional paid-in capital increased from Dec. 2020 (£88.35 Mil) to Dec. 2021 (£114.58 Mil) and increased from Dec. 2021 (£114.58 Mil) to Dec. 2022 (£116.26 Mil).

Shield Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Shield Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Additional Paid-In Capital Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

88.34

88.35

114.58

116.26

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial													114.58	114.58	114.64	116.26	173.09

Shield Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Shield Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.